Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.
Also called NCT01388361
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 413 participants
- Sponsor
- Registry
-
NCT01388361 -
2011-001493-25
-
- Other papers using this trial's data
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Norway, Serbia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01388361. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-07 (actual). Results posted on 2015-11-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
- Acronym
- BEGIN™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin aspart
- Intervention (Drug)
- liraglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01388361- Content hash
1067e75ebf565f506baa758360366cc5b9361c0052f3b8e8a3f6400b54c13f83